Study summary: The CLARITY AD Phase III Trial

Notice: Blog posts are not subject to review by MedLink Neurology’s Editorial Board. MedLink acknowledges using artificial intelligence to assist in the creation of blog posts.

Objective

To evaluate the efficacy and safety of lecanemab, a monoclonal antibody targeting soluble and insoluble aggregated forms of amyloid beta, in patients with early Alzheimer disease—specifically those with mild cognitive impairment or mild dementia due to Alzheimer disease and confirmed amyloid pathology.

Study design

• Randomized, double-blind, placebo-controlled
• Treatment: lecanemab 10 mg/kg intravenously every 2 weeks
• Duration: 18 months
• Participants: 1,795 patients (mean age approximately 72 years) with early Alzheimer disease

Primary endpoint

Change from baseline in the CDR-SB score (Clinical Dementia Rating–Sum of Boxes) at 18 months

Key results

• Lecanemab significantly slowed clinical decline:
• Mean CDR-SB worsening was 1.21 points with lecanemab versus 1.66 points with placebo
• 27% less decline over 18 months (p < 0.001)
• Secondary endpoints (eg, ADAS-Cog14, ADCOMS, MMSE) also showed statistically significant benefit favoring lecanemab.
• Amyloid PET imaging confirmed significant amyloid clearance in the treatment group.
• Adverse events:
• ARIA-E (edema) occurred in approximately 12.6% of patients receiving lecanemab
• ARIA-H (hemorrhage) was seen in approximately 17.3%
• Most ARIA cases were asymptomatic or mild, but serious adverse events did occur, particularly in patients on anticoagulants.

Implications for clinical practice

1. Proof-of-concept for anti-amyloid therapy:
• CLARITY AD provides the clearest evidence to date that targeting amyloid in early Alzheimer disease modestly slows clinical decline.
• The magnitude of effect is modest, but clinically meaningful in certain patient populations.
2. FDA approval and labeling:
• The trial supported full FDA approval of lecanemab (Leqembi®) in July 2023 for patients with early symptomatic Alzheimer disease and confirmed amyloid pathology.
• Approved with a boxed warning due to risks of ARIA.
3. Patient selection and risk stratification:
• Appropriate for patients with:
• Mild cognitive impairment or mild Alzheimer disease dementia
• Positive amyloid biomarkers
• No contraindications (eg, active bleeding risk)
• Caution in APOE4 carriers and those on anticoagulation, due to increased ARIA risk.
4. Access and health system considerations:
• High cost (approximately $26,500/year) and requirement for serial MRIs and amyloid confirmation pose barriers.
• Coverage under Medicare is conditional on participation in CMS-mandated registries to track real-world outcomes.

Clinical perspective

Lecanemab represents a modest but meaningful step forward in the management of early Alzheimer disease. Although it is not curative, it supports the amyloid hypothesis and may delay the need for full-time care or institutionalization for select patients. The trial also signals a shift toward biomarker-driven, disease-modifying therapies in dementia, with broader implications for diagnosis, monitoring, and healthcare delivery.

Are you interested in contributing a post or becoming a guest blogger for MedLink? Contact us at editorial@medlink.com.